Playback speed
10 seconds
ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment for Unresectable RAS and BRAF Wild-Type mCRC: Results of the Phase III Randomized TRIPLETE Study by GONO
By
ASCO 2022 Conference Coverage
FEATURING
Chiara Cremolini
By
ASCO 2022 Conference Coverage
FEATURING
Chiara Cremolini
0 views
June 10, 2022
Comments 0
Login to view comments.
Click here to Login